Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa

Completed · Phase 3

Conditions studied: Epidermolysis Bullosa

In brief

This was a Phase III, Efficacy and Safety Study of Oleogel-S10 in Participants with Inherited Epidermolysis Bullosa (EB). EB is a rare group of genetic skin fragility disorders characterised by blistering of the skin in response to minor injury. In most cases, onset of EB is at birth or shortly after. All participants affected by any type of EB share the main characteristic of repeatedly developing painful wounds that take days to months to heal. Current treatment of EB is primarily preventative and supportive including protection from mechanical forces by avoiding rubbing, early treatment of wounds to prevent infections, and protection of the wound with adequate non-adhesive dressings to enable healing. The active pharmaceutical ingredient in Oleogel-S10 is a refined birch bark extract, quantified to 72 to 88% betulin. This clinical study of Oleogel-S10 in patients with inherited EB has been carried out to investigate whether Oleogel-S10 is effective for treatment of EB wounds and safe for long-term use. Oleogel-S10 was compared to a control gel. The control gel matched Oleogel-S10 in terms of texture and visual appearance to allow for double-blinding. The packaging for Oleogel-S10 gel and the control gel were identical. The participant received either Oleogel-S10 or control gel for a double-blind study phase of 90 days. The probability that the participant received Oleogel-S10 was 50%, which means that they had a 1 in 2 chance of receiving Oleogel-S10. However, in the follow-up phase of the study all participants were treated with Oleogel-S10 for a period of 24 months. This clinical study was performed at 49 study sites in 26 countries (Argentina, Australia, Austria, Brazil, Chile, Colombia, Czech Republic, Denmark, France, Georgia, Germany, Greece, Hong Kong \[China\], Hungary, Ireland, Israel, Italy, Romania, Russia, Serbia, Singapore, Spain, Switzerland, Ukraine, United Kingdom, and the United States); 223 participants participated in total.

Key facts

Study ID: NCT03068780
Run by: Amryt Research Limited
People needed: 223
Starts: 2017-03-29
Expected to finish: 2022-05-27
Last updated by the study team: 2023-07-20

Who can join

Age: 0 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male and female patients with the following subtypes of inherited EB: junctional EB (JEB), dystrophic EB (DEB), and Kindler EB aged ≥21 days
Patients with an EB target wound (i.e., EB partial thickness wound of 10 cm² to 50 cm² in size aged ≥21 days and <9 months)
Patient and/or his/her legal representative has/have been informed, has/have read and understood the patient information/informed consent form, and has/have given written informed consent
Patient and/or his/her legal representative must be able and willing to follow study procedures and instructions

You may not qualify if…

Patient has EB simplex
EB target wound that is ≥9 months old or has clinical signs of local infection
Use of systemic antibiotics for wound-related infections within 7 days prior to enrolment
Administration of systemic or topical steroids (except for inhaled, ophthalmic or topical applications, such as budesonide suspension for oesophageal strictures [e.g., Pulmicort respules® 0.25 mg/2 mL or 0.5 mg/2 mL]) within 30 days before enrolment
Immunosuppressive therapy or cytotoxic chemotherapy within 60 days prior to enrolment
Patient has undergone stem cell transplant or gene therapy for the treatment of inherited EB
Current and/or former malignancy including basal cell carcinomas and squamous cell carcinomas
Enrolment in any interventional study or treated with any investigational drug for any disease within 4 weeks prior to study entry
Factors present in the patient and/or his/her legal representative that could interfere with study compliance such as inability to attend scheduled study visits or compliance with home dressing changes
Pregnant or nursing women and women of childbearing potential including postmenarchal female adolescents not willing to use an effective form of birth control with failure rates <1% per year (e.g., implant, injectable, combined oral contraceptive, intrauterine contraceptive device, sexual abstinence, vasectomised partner) during participation in the study (and at least 3 months thereafter)
Patient is a member of the investigational team or his/her immediate family
Patient lives in the same household as a study participant

Where it is running

Children's Hospital Colorado — Aurora, Colorado, United States
Amjad Plastic Research — Miami, Florida, United States
University of Minnesota — Minneapolis, Minnesota, United States
Stony Brook University Hospital — Stony Brook, New York, United States
Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
The Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital — Philadelphia, Pennsylvania, United States
Medical University of South Carolina — Charleston, South Carolina, United States
Texas Dermatology and Laser Specialists — San Antonio, Texas, United States
Consutorios Medicos (Instituto de Neumonologia y Dermatologia) — Buenos Aires, Argentina
Centro Médico Dra. De Salvo — Buenos Aires, Argentina
Centro de investigaciones Metabolicas, CINME — Buenos Aires, Argentina
Sydney Children's Hospital — Sydney, New South Wales, Australia
Premier Specialists — Sydney, New South Wales, Australia
The Royal Melbourne Hospital — Parkville, Victoria, Australia
Murdoch Childrens Research Institute Royal Children's Hospital — Parkville, Victoria, Australia
Universitaetsklinik fuer Dermatologie — Salzburg, Austria
IMIP — Recife, Pernanbuco, Brazil
Universidade Regional de Blumenau — Blumenau, Santa Catarina, Brazil
Instituto Da Crianca HCFMUSP — São Paulo, Brazil
Fundacion Debra Chile — Santiago, Chile
Hospital De San Jose — Bogotá, DC, Colombia
University Hospital Brno, Children´s Hospital — Brno, Czechia
Aarhus University Hospital — Aarhus, Denmark
Phoenix Children's Hospital — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.